key: cord-0682934-t9pqj902
authors: Ishikura, Hiroyasu; Maruyama, Junichi; Hoshino, Kota; Matsuoka, Yuta; Yano, Masaya; Arimura, Tadaaki; Katano, Harutaka; Kato, Seiya; Kitamura, Taisuke; Nakamura, Yoshihiko
title: Coronavirus disease (COVID-19) associated delayed-onset fulminant myocarditis in patient with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
date: 2021-08-12
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.08.007
sha: b9aff7252cc0a8d2d415dfde8cda1e13291e51e2
doc_id: 682934
cord_uid: t9pqj902

A healthy 35-year-old man was admitted to a rural hospital with coronavirus disease (COVID-19). During 14 days of hospitalization, he had no symptoms and was not given supplemental oxygen. About 3 weeks after discharge, he was re-admitted to the same hospital with new-onset continuous fever and general weakness. At the time of his second admission, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RT-PCR was performed on a retro-nasal swab and the result was negative. Four days after admission, the patient was transferred to our intensive care unit (ICU) following deterioration of his respiratory and haemodynamic conditions, where he received mechanical ventilation, intra-aortic balloon pumping, and veno-arterial extracorporeal membrane oxygenation. A nasopharyngeal swab was obtained again at ICU admission, but RT-PCR was negative for SARS-CoV-2. All antibody titres measured against other viruses were low. Blood cultures were negative, and no bacteria were observed in sputum samples. However, SARS-CoV-2 RNA was detected by RT-PCR from sections obtained by myocardial biopsy. The patient’s final diagnosis was delayed-onset SARS-CoV-2-induced fulminant myocarditis (FM). We strongly suggested that one of the proposed mechanisms of COVID-19-related myocardial injury will be the direct invasion of SARS-CoV-2 into cardiomyocytes even if delayed-onset. And this is the first case of delayed-onset FM in which diagnosis of active myocarditis was proven by pathological examination following endomyocardial biopsy and SARS-CoV-2 was detected in the myocardium by RT-PCR.

A healthy 35-year-old man was admitted to a rural hospital with coronavirus disease . During 14 days of hospitalization, he had no symptoms and was not given supplemental oxygen. About 3 weeks after discharge, he was re-admitted to the same hospital with new-onset continuous fever and general weakness. At the time of his second admission, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RT-PCR was performed on a retro-nasal swab and the result was negative. Four days after admission, the patient was transferred to our intensive care unit (ICU) following deterioration of his respiratory and haemodynamic conditions, where he received mechanical ventilation, intra-aortic balloon pumping, and veno-arterial extracorporeal membrane oxygenation. A nasopharyngeal swab was obtained again at ICU admission, but RT-PCR was negative for SARS-CoV-2. All antibody titres measured against other viruses were low. Blood cultures were negative, and no bacteria were observed in sputum samples. However, SARS-CoV-2 RNA was detected by RT-PCR from sections obtained by myocardial biopsy. The patient's final diagnosis was delayed-onset SARS-CoV-2induced fulminant myocarditis (FM). We strongly suggested that one of the proposed mechanisms of COVID-19-related myocardial injury will be the direct invasion of SARS-CoV-2 into cardiomyocytes even if delayed-onset. And this is the first case of delayed-J o u r n a l P r e -p r o o f onset FM in which diagnosis of active myocarditis was proven by pathological examination following endomyocardial biopsy and SARS-CoV-2 was detected in the myocardium by RT-PCR. It is now well established that many COVID-19 patients, especially those with severe disease, experience complications including acute respiratory distress syndrome (ARDS), shock, coagulation/fibrinolysis abnormalities, stroke, acute kidney injury, and acute cardiac injury [2] . And cardiovascular complications occur in 7.2% [2] . Thus, cardiovascular complications are not infrequent in COVID-19 patients. However, to date only elevated cardiac troponin I (TropI) levels and arrhythmia have been reported in COVID-19 patients, and no specific investigations of the effects of SARS-CoV-2 infection on the cardiovascular system have been conducted [3] .

Here, we describe the first case of delayed-onset fulminant myocarditis (FM) in which diagnosis of active myocarditis was proven by pathological examination following endomyocardial biopsy and SARS-CoV-2 was detected in the myocardium by RT-PCR J o u r n a l P r e -p r o o f over 3 weeks after complete recovery from COVID-19.

Seven days after onset of upper respiratory tract symptoms, a healthy 35-year-old man was consulted at a rural hospital. He had no medical history of cardiovascular disease or cardiovascular risk factors. He was diagnosed with COVID-19 after SARS-CoV-2 was detected by RT-PCR from a nasopharyngeal swab sample. He was admitted to the rural hospital. During admission, he denied chest pain, dyspnoea, and other symptoms, and was not given supplemental oxygen. He was discharged and returned home on the 14 th day after admission. About 3 weeks after discharge, he was re-admitted to the same hospital with new-onset continuous fever and general weakness. At his second admission, SARS-CoV-2 RT-PCR was performed on a retro-nasal swab and the result was negative. Four days after admission, he was transferred to our intensive care unit following a sudden deterioration in respiratory and hemodynamic conditions. On arrival to the ICU under mechanical ventilation, physical examination revealed a blood pressure of 73/34 mmHg (during administration of 0.3 γ of noradrenaline and 2 units/hour of vasopressin by continuous intravenous injection), a heart rate of 147 bpm, and a body temperature of 36.6°C. Arterial blood gas analysis showed oxygen partial pressure of 82 mmHg, carbon dioxide partial pressure of 32 mmHg, and a PaO2/FiO2 ratio of 166 ( Figure 1 ).

An electrocardiogram ( Given the severity of his cardiogenic shock, the patient underwent intra-aortic balloon pumping (IABP) and veno-arterial extracorporeal membrane oxygenation (V-A ECMO).

He was also treated with intravenous immunoglobulin, steroids, continuous renal J o u r n a l P r e -p r o o f replacement therapy (CRRT) and antiviral therapy (intravenous injection of nafamostat mesylate [4, 5] as an anticoagulant for CRRT) (Figure 1 ).

The patient ultimately recovered ventricular function and withdrew from V-A ECMO, IABP, mechanical ventilation, and CRRT 1-2 weeks after admission.

The final diagnosis was delayed SARS-CoV-2-induced FM based on the detection of SARS-CoV-2 in pathological specimens of the myocardium by RT-PCR. The patient was transferred to the previous hospital for rehabilitation on the 24 th day after admission.

In nearly all previously published cases, acute heart failure and/or left ventricular dysfunction occurred within the first week following the initial symptoms of COVID-19 [6] . Only two cases had delays of approximately 4 and 6 weeks, respectively, from initial COVID-19-related symptoms to the onset of acute heart failure [6, 7] . Our case had a delay of over 3 weeks from initial COVID-19 symptoms to onset of FM.

A few case reports of acute heart failure and/or left ventricular dysfunction with abnormalities on cardiac magnetic resonance imaging suggestive of myocarditis have been published in the setting of acute SARS-CoV-2 infection; however, diagnosis of active myocarditis was proven by pathological examination following endomyocardial J o u r n a l P r e -p r o o f biopsy in only two cases [6, 8] . In our case, diagnosis of active myocarditis was made by pathological examination following endocardial myocardial biopsy.

For the previous two patients who developed acute heart failure more than a month after the first COVID-19-related symptoms, one case reported by Nicol et al. [6] , RT-PCR was performed using frozen myocardial fragments to exhaustively search for viruses. SARS-CoV-2 was not detected. The other case reported by Spano et al. [7] , RT-PCR was not performed for the purpose of detecting SARS-CoV-2. We detected SARS-CoV-2 by RT-PCR in pathological specimens of the myocardium from our patient. For the above reasons, we concluded that ours was the first case of laboratory-confirmed FM. However, the mechanism of delayed FM in COVID-19 patients remains unclear at this time.

FM is a rare clinical syndrome with features of cardiac inflammation, and has a high mortality rate of approximately 30% at 60 days [9] . Acute myocarditis is an inflammatory disease of the myocardium most often resulting from viral infections or autoimmune disorders [10] . Since Zing et al. reported the first case of COVID-19 with FM [11], several additional cases of COVID-19-associated FM have been reported including in a healthy young patient [12] and an infant [13] . Some authors have argued that up to 7% of COVID-19-related deaths were attributable to myocarditis [14] . The case reported here had a sudden disease onset, obvious symptoms of viral infection, rapid emergence of severe J o u r n a l P r e -p r o o f mediated by interactions between SARS-CoV-2 and ACE2, contributes to myocardial injury. This pathophysiological mechanism of myocardial injury following COVID-19 may be a characteristic of SARS-CoV-2-induced FM.

IL-6 levels in this case reported here never exceeded 600 pg/mL during his ICU stay.

These values are not high enough to be called a cytokine storm. Leisman et al [18] .

proposed that IL-6 concentrations in patients with severe or critical COVID-19 were significantly lower than in patients with sepsis or ARDS unrelated to COVID-19. Thus, the role of a cytokine storm in COVID-19-induced FM may be questionable.

Previously, SARS-CoV RNA was detected in 35% (7⁄20) of autopsied human heart samples, and a marked increase in macrophage infiltration with evidence of myocardial damage was observed in patients with detectable SARS-CoV RNA [19] . Diagnosis of FM can be aided through use of biomarkers and cardiac imaging. However, endocardial biopsy remains the gold standard, although its sensitivity may be limited by patchy distribution of inflammatory infiltrates [20] . In this case we performed endocardial biopsy, and SARS-CoV-2 RNA was detected by RT-PCR. Kesici et al [13] . previously reported that SARS-CoV-2 RT-PCR was positive in the myocardium from a patient with COVID-19-related FM.

In conclusion, we suggest that a potential mechanism of FM in COVID-19 patients J o u r n a l P r e -p r o o f may be direct SARS-CoV-2 invasion of the myocardium. Therefore, clinicians should remain vigilant for delayed-onset COVID-19-associated FM even after patients have completely recovered from COVID-19.

This case report did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

None.

Because of the unique and potentially identifiable characteristics of COVID-19, we obtained signed informed consent from the patient in accordance with the Declaration of Helsinki for publication of this case report. A copy of the informed consent document can be provided upon request. 

disorders, severe myocardial injury, and diffuse decreased ventricular wall movement. These features are all in accordance with the diagnostic criteria for FM

The pathophysiological mechanisms underlying the myocardial injuries caused by COVID-19 are not well understood so far. We suggested the mechanisms of cardiovascular complications associated with COVID-19 as follow: (i) direct SARS-CoV-2 invasion of the myocardium, (ii) systemic inflammation mediated by acute systemic inflammatory responses and cytokine storms, (iii) altered myocardial demand supply ratio, plaque rupture, and coronary thrombosis, (iv) adverse effects of various therapies, and/or (v) electrolyte imbalances

SARS-CoV-2 is an enveloped RNA betacoronavirus in the same family as SARS-CoV. In humans, SARS-CoV infection of the myocardium is dependent on expression of ACE2 receptors. Oudit et al. [17] reported that SARS-CoV viral RNA was detected in autopsied human heart samples, suggesting direct viral invasion of myocytes. The authors hypothesized that interaction between SARS-CoV and ACE2 in the heart contributed to SARS-mediated myocardial inflammation

The epidemiology and clinical information about COVID-19

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

SARS-CoV-2: A potential novel etiology of fulminant myocarditis

Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner Viruses

Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome

Delayed isolated peri-myocarditis in a Covid-19 patient with respiratory symptoms but without lung involvement

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction

First case of COVID-19 complicated with fulminant myocarditis: A case report and insights

Myocarditis revealing COVID-19 infection in a young patient

Fulminant COVID-19-related myocarditis in an infant

Cardiovascular considerations for patients, health care workers, and health systems

Predictors of outcome in patients with suspected myocarditis

SARScoronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area

Fulminant myocarditis: Epidemiology, pathogenesis, diagnosis, and management

We would like to thank the nursing staff involved in this patient's care, members of the Infection Prevention and Control team, and members of the Cardiovascular Catheter team.We also thank Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.